Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

ClinicalTrials.gov ID: NCT00122330

Public ClinicalTrials.gov record NCT00122330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients

Study identification

NCT ID: NCT00122330
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 75 participants

Conditions and interventions

Conditions

Hemoglobinuria, Paroxysmal

Interventions

eculizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2004
Primary completion: Not listed
Completion: Dec 31, 2005
Last update posted: Dec 3, 2006

2004 – 2006

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
City of Hope National Medical Center, Div. of Hematology & Bone Marrow Transplant	Duarte	California	91010-3000	—
University of California at Los Angeles	Los Angeles	California	90024	—
Scripps Cancer Center	San Diego	California	92121	—
Stanford University Medical Center, Division of Hematology	Stanford	California	94305-5821	—
Hartford Hospital, Cancer Clinical Research Office	Hartford	Connecticut	06102	—
Cleveland Clinic, Dept. of Clinical Research	Weston	Florida	33331	—
Indiana University Cancer Pavilion, Div. of Hematology-Oncology, Hematological Malignancy Program/Immunology	Indianapolis	Indiana	46202	—
Johns Hopkins University Medical Center	Baltimore	Maryland	21205	—
National Heart, Blood, and Lung Institute, National Institutes of Health	Bethesda	Maryland	20892	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology	St Louis	Missouri	63110-1093	—
NYU Clinical Cancer Center	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10021	—
Duke University Health System, Division of Cell Therapy, Heme Malignancies Program	Durham	North Carolina	27710	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program	Philadelphia	Pennsylvania	19104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00122330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 3, 2006 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00122330 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →